[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201690874A1 - PREVENTING ABUSE OF GRANULATED MEDICINAL FORMS WITH IMMEDIATE RELIEF - Google Patents

PREVENTING ABUSE OF GRANULATED MEDICINAL FORMS WITH IMMEDIATE RELIEF

Info

Publication number
EA201690874A1
EA201690874A1 EA201690874A EA201690874A EA201690874A1 EA 201690874 A1 EA201690874 A1 EA 201690874A1 EA 201690874 A EA201690874 A EA 201690874A EA 201690874 A EA201690874 A EA 201690874A EA 201690874 A1 EA201690874 A1 EA 201690874A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immediate relief
medicinal forms
preventing abuse
abuse
dosage forms
Prior art date
Application number
EA201690874A
Other languages
Russian (ru)
Other versions
EA032013B1 (en
Inventor
Динеш К. Хасвани
Дерек В. Мое
Виктория А. О'Нейлл
Мануэль А. Вега Сепеда
Original Assignee
Сайма Лэбс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/047014 external-priority patent/WO2015065547A1/en
Application filed by Сайма Лэбс Инк. filed Critical Сайма Лэбс Инк.
Publication of EA201690874A1 publication Critical patent/EA201690874A1/en
Publication of EA032013B1 publication Critical patent/EA032013B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны пероральные лекарственные формы с немедленным высвобождением, которые включают препятствующие злоупотреблению характеристики. В частности, описанные лекарственные формы обеспечивают препятствие злоупотреблению посредством приема нескольких отдельных доз. Кроме того, описанные лекарственные формы обеспечивают защиту от передозировки в случае непредумышленного или предумышленного приема нескольких отдельных доз.Immediate release oral dosage forms have been described that include anti-abuse characteristics. In particular, the dosage forms described provide an obstacle to abuse by taking several separate doses. In addition, the dosage forms described provide protection against overdose in the event of inadvertently or deliberately taking several separate doses.

EA201690874A 2013-10-31 2014-10-29 Immediate release abuse-deterrent granulated dosage forms EA032013B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361898207P 2013-10-31 2013-10-31
PCT/US2014/047014 WO2015065547A1 (en) 2013-10-31 2014-07-17 Immediate release abuse-deterrent granulated dosage forms
US14/333,986 US20150118300A1 (en) 2013-10-31 2014-07-17 Immediate Release Abuse-Deterrent Granulated Dosage Forms
US14/477,354 US20150118301A1 (en) 2013-10-31 2014-09-04 Immediate Release Abuse-Deterrent Granulated Dosage Forms
PCT/US2014/054061 WO2015065586A1 (en) 2013-10-31 2014-09-04 Immediate release abuse-deterrent granulated dosage forms
US14/484,793 US20150118295A1 (en) 2013-10-31 2014-09-12 Immediate Release Abuse-Deterrent Granulated Dosage Forms
PCT/US2014/062887 WO2015066172A1 (en) 2013-10-31 2014-10-29 Immediate release abuse-deterrent granulated dosage forms

Publications (2)

Publication Number Publication Date
EA201690874A1 true EA201690874A1 (en) 2016-08-31
EA032013B1 EA032013B1 (en) 2019-03-29

Family

ID=53005066

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690874A EA032013B1 (en) 2013-10-31 2014-10-29 Immediate release abuse-deterrent granulated dosage forms

Country Status (5)

Country Link
EP (1) EP3062778A4 (en)
CA (1) CA2900858C (en)
EA (1) EA032013B1 (en)
IL (1) IL245125B (en)
WO (1) WO2015066172A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3229788A4 (en) * 2014-12-08 2018-06-13 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2018044895A1 (en) * 2016-08-29 2018-03-08 Cima Labs Inc. Immediate release dosage forms with abuse deterrence and alcohol resistance
BR112020023882A2 (en) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. method to treat major depressive disorder
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
WO2001080826A2 (en) * 2000-04-20 2001-11-01 Bristol-Myers Squibb Company Taste masking coating composition
CN1525851A (en) * 2001-05-11 2004-09-01 ������ҩ�����޹�˾ Abuse-resistant controlled-release opioid dosage form
WO2008134071A1 (en) * 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
CN105534936B (en) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 Abuse resistant drugs, methods of use and methods of preparation
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
EP2635258A1 (en) * 2010-11-04 2013-09-11 AbbVie Inc. Drug formulations
PE20142320A1 (en) * 2012-03-02 2015-01-16 Rhodes Pharmaceuticals Lp IMMEDIATE RELEASE FORMULATIONS RESISTANT TO HANDLING

Also Published As

Publication number Publication date
EA032013B1 (en) 2019-03-29
EP3062778A1 (en) 2016-09-07
IL245125B (en) 2021-06-30
EP3062778A4 (en) 2017-07-19
IL245125A0 (en) 2016-06-30
CA2900858A1 (en) 2015-05-07
CA2900858C (en) 2017-05-02
WO2015066172A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
MX2016005482A (en) Immediate release abuse-deterrent granulated dosage forms.
EA201690874A1 (en) PREVENTING ABUSE OF GRANULATED MEDICINAL FORMS WITH IMMEDIATE RELIEF
CY1123571T1 (en) BUPROPIONE FOR THE ADJUSTMENT OF PHARMACEUTICAL DEXTROMETHORPHAN PLASMA LEVELS
MX2021000550A (en) Tofacitinib oral sustained release dosage forms.
CL2015003022A1 (en) Use of empagliflozin in the preparation of a useful medication in the treatment of chronic kidney disease
NZ745556A (en) Androgen receptor modulator and uses thereof
MY187540A (en) Compounds active towards bromodomains
DK2819726T3 (en) STANDARD DOSAGE ADMINISTRATION DEVICE
EA201600100A1 (en) PROTECTED FROM APPLICATION NOT ACCORDING TO THE DOSAGE FORM, CONTAINING ETHYLENEVINYL ACETABLE POLYMER
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
EP3242650A4 (en) Dosage form incorporating an amorphous drug solid solution
CL2015002677A1 (en) Compositions comprising selenium and their use for the treatment and prevention of diseases or conditions associated with mitochondrial dysfunction.
EA201500742A1 (en) PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE
NZ629332A (en) Treatment of cancer with dihydropyrazino-pyrazines
BR112015023523B8 (en) PHARMACEUTICAL COMPOSITIONS AND SINGLE DOSAGE FORM CONTAINER
EP3481381A4 (en) Oral dosage form with drug composition, barrier layer and drug layer
MX2016006688A (en) Tetracyclic autotaxin inhibitors.
MX2021007899A (en) Selective il-6-trans-signalling inhibitor compositions.
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
MX2016006087A (en) Rapidly disintegrating formulations and methods of use.
AU2014271207A1 (en) Targeted delivery of drugs to the myometrium
EP2999461A4 (en) Targeted delivery of drugs to the myometrium
TWI800759B (en) Pharmaceutical dosage forms
MX2016002560A (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir.
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM